Affordable Access

deepdyve-link
Publisher Website

Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity.

Authors
  • Szefler, Stanley J1
  • Casale, Thomas B2
  • Haselkorn, Tmirah3
  • Yoo, Bongin4
  • Ortiz, Benjamin5
  • Kattan, Meyer6
  • Busse, William W7
  • 1 Pediatric Asthma Research Program, Breathing Institute, Children's Hospital Colorado, and University of Colorado School of Medicine, Aurora, Colo. Electronic address: [email protected]renscolorado.org.
  • 2 University of South Florida, Tampa, Fla.
  • 3 EpiMetrix, Inc, Los Altos, Calif.
  • 4 Genentech, Inc, South San Francisco, Calif.
  • 5 Novartis Pharmaceuticals Corporation, East Hanover, NJ.
  • 6 Columbia University College of Physicians and Surgeons, New York, NY.
  • 7 University of Wisconsin School of Medicine and Public Health, Madison, Wis.
Type
Published Article
Journal
The journal of allergy and clinical immunology. In practice
Publication Date
Sep 01, 2020
Volume
8
Issue
8
Identifiers
DOI: 10.1016/j.jaip.2020.03.033
PMID: 32298853
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Greater severity in childhood asthma negatively impacts functioning and quality of life. Omalizumab is effective in children aged 6 years or older with moderate to severe persistent asthma, but predicting responsiveness in severe disease requires further study. To assess response to omalizumab treatment among children using indicators of asthma severity. Post hoc analyses of randomized placebo-controlled studies of omalizumab (Inner-City Anti-IgE Therapy for Asthma [ICATA], IA05, and Preventative Omalizumab or Step-up Therapy for Fall Exacerbations [PROSE]) stratified by body mass index, eosinophil count, fractional exhaled nitric oxide levels, and baseline severity indicators (baseline percent predicted FEV1, previous hospitalizations, asthma exacerbations). Poisson regression analysis examined exacerbation rate reductions for body mass index, biomarkers, and severity indicators. Children aged 6 to 11 years in IA05 (N = 576; 56% white, 17% black, 26% other/missing), ICATA (N = 237; 55% black, 43% Hispanic), and PROSE (N = 342; 59% black, 35% Hispanic) were included. Trends indicative of greater exacerbation rate change ([omalizumab - placebo]/placebo) were observed for low baseline lung function (IA05 percent predicted FEV1: <90%, 36% reduction, 95% CI, -53.3 to -13.5; ≥90%, 22% reduction, 95% CI, -52.1 to 27.5), previous hospitalizations (ICATA: 46% reduction with, 95% CI, -69.7 to -3.9; 24% reduction without, 95% CI, -48.1 to 10.3), frequent baseline exacerbations (IA05: ≥3, 42% reduction, 95% CI, -60.4 to -14.1; <3, 20% reduction, 95% CI, -45.2 to -15.9), and high baseline eosinophil count (IA05: ≥300 cells/μL, 39% reduction, 95% CI, -56.4 to -14.7; <300 cells/μL, 5% reduction, 95% CI, -40.6 to 52.1). Omalizumab reduces exacerbations in children with moderate to severe persistent allergic asthma, and may provide greater benefit in children with more severe asthma subtypes. Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times